Ipamorelin
Research Use Only | Not for Human Consumption
A synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NHu2082)
Ipamorelin is a synthetic pentapeptide and growth hormone secretagogue receptor (GHS-R1a) agonist. In preclinical investigations, it has been examined for interactions with the ghrelin-receptor pathway and for selectivity relative to ACTH, cortisol, and prolactin pathways.
| CAS# | Formula | Molar Mass |
|---|---|---|
| 170851-70-4 | C₃₈H₄₉N₉O₅ | 711.9 g/mol |
All products are shipped in lyophilized form and must be reconstituted for in-vitro research applications. Refer to the Certificate of Analysis for purity and identity specifications.
A synthetic pentapeptide GHS-R1a agonist
What is Ipamorelin?
Ipamorelin was developed by scientists at Novo Nordisk in Denmark during the late 1990s. Researchers were investigating growth hormone secretagogues and sought a compound with a narrower receptor-interaction profile than earlier GHRPs such as GHRP-6, which had been associated with changes in cortisol levels and appetite-related signaling in preclinical work.
The Novo Nordisk team designed Ipamorelin as a pentapeptide targeting the ghrelin receptor (GHS-R1a). In their characterization work, published by Raun and colleagues in 1998, they reported GH release with minimal measured effects on ACTH, cortisol, or prolactin in the preclinical models examined.
Since that initial characterization, Ipamorelin has appeared in peer-reviewed preclinical publications examining GHS-R1a pharmacology, pharmacokinetic modeling, and skeletal endpoints in rodent models. This product is intended for research use only.
What is Ipamorelin studied for?
The following research areas represent documented studies available in the scientific literature. We make no claims regarding the benefits, efficacy, or therapeutic applications of this product.
GHS-R1a Selectivity Research
In preclinical characterization studies, ipamorelin has been examined as a GHS-R1a agonist with a selectivity profile distinct from earlier GHRPs regarding ACTH and cortisol pathways.
Pharmacokinetic & Pharmacodynamic Research
Phase I pharmacokinetic-pharmacodynamic modeling has characterized ipamorelin's dose-exposure relationship and associated GH concentration profiles in healthy volunteers.
Bone Mineral Content Research
Preclinical studies in adult female rats have examined ipamorelin's associations with bone mineral content and long-bone dimensional measurements.
Glucocorticoid-Model Research
In rodent glucocorticoid-challenge models, ipamorelin has been investigated for its interactions with skeletal muscle and bone-formation endpoints under catabolic conditions.
How should Ipamorelin be stored?
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months.
Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability.
After reconstitution, the peptides will remain stable for up to 30 days.
Certificate of Analysis
All Ipamorelin batches are independently tested by a third-party laboratory for purity and identity verification via HPLC with UV detection coupled with Mass Spectrometry.
HPLC Purity
—
No Certificate of Analysis is available for the selected size yet. Contact support for batch-specific documentation.
COA documents are updated with each new batch. Contact support for batch-specific documentation.
Related Research Compounds
Frequently purchased with Ipamorelin
Add all 3 items to your cart
$325
Clinical References
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PubMed: 9849822
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide. Pharmaceutical Research. 1999. PubMed: 10496658
- Svensson J, et al. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. Journal of Endocrinology. 2000. PubMed: 10828840
- Ghigo E, et al. Growth hormone secretagogues: clinical applications. Journal of Endocrinological Investigation. 1997.
